Evofem Biosciences Total Liabilities 2013-2022 | EVFM

Evofem Biosciences total liabilities from 2013 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Evofem Biosciences Annual Total Liabilities
(Millions of US $)
2021 $142
2020 $109
2019 $13
2018 $27
2017 $104
2016 $1
2015 $16
2014 $12
2013 $2
2012 $2
Evofem Biosciences Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $159
2021-12-31 $142
2021-09-30 $126
2021-06-30 $100
2021-03-31 $107
2020-12-31 $109
2020-09-30 $72
2020-06-30 $67
2020-03-31 $15
2019-12-31 $13
2019-09-30 $15
2019-06-30 $19
2019-03-31 $32
2018-12-31 $27
2018-09-30 $25
2018-06-30 $21
2018-03-31 $27
2017-12-31 $104
2017-09-30 $1
2017-06-30 $2
2017-03-31 $2
2016-12-31 $1
2016-09-30 $1
2016-06-30 $7
2016-03-31 $7
2015-12-31 $16
2015-09-30 $20
2015-06-30 $15
2015-03-31 $13
2014-12-31 $12
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $2
2012-12-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.008B
Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00